A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Latest Information Update: 08 Apr 2024
At a glance
- Drugs Atezolizumab (Primary) ; Docetaxel; Paclitaxel; Pertuzumab; Trastuzumab
- Indications Adenocarcinoma; Advanced breast cancer; Brain metastases; HER2 positive breast cancer; Male breast cancer
- Focus Therapeutic Use
- 18 Jan 2023 Planned End Date changed from 31 Jan 2023 to 30 Apr 2024.
- 18 Jan 2023 Planned primary completion date changed from 31 Jan 2023 to 30 Apr 2024.
- 24 Aug 2022 Time frame of evaluation of primary endpoint changed from 7 years to every 6 months, assessed up to 8 years.